Some people’s triglycerides go down when they take omega-3 fish oil, but others don’t see any change—not because they’re not taking it right, but because their genes make them respond differently. So, we might need blood tests or genetic scans to figure out who will actually benefit.
Evidence Quality Assessment
Claim Status
appropriately stated
Study Design Support
Design supports claim
Appropriate Language Strength
probability
Can suggest probability/likelihood
Assessment Explanation
The claim acknowledges variability and proposes a mechanistic explanation (genetic/epigenetic) for non-response, which is consistent with emerging pharmacogenomic literature. The 26% figure suggests a quantitative observation from prior studies, and the conclusion about biomarker-guided therapy is a reasonable inference—not a definitive assertion. The use of 'likely due to' and 'suggesting' appropriately reflects probabilistic reasoning. The claim avoids overstatement by not claiming causation or universal applicability.
More Accurate Statement
“Inter-individual variability in triglyceride-lowering response to omega-3 supplementation is likely influenced by genetic and epigenetic factors rather than poor adherence, suggesting that biomarker-guided therapy could improve response rates in clinical practice.”
Context Details
Domain
nutrition
Population
human
Subject
Inter-individual variability in response to omega-3 supplementation
Action
is likely due to
Target
genetic and epigenetic differences, not poor compliance, suggesting a need for biomarker-guided therapy
Intervention Details
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.
Evidence from Studies
Supporting (1)
This study says that omega-3 supplements don’t work for everyone, and it’s probably because of differences in people’s genes and biology—not because they didn’t take the pills. It suggests we should test people first to see who will benefit.